Cardiac safety studies depend on certainty at every time point
DVCR supports Early QT/TQT studies with experienced teams, dedicated telemetry infrastructure, Clario integration and workflows designed to protect ECG data quality.
Discuss your clinical development program.
This form is for sponsor and CRO partnership inquiries. Share a few details about your upcoming study, and our team will follow up.
Looking to participate in a study? Visit our volunteer website.
A clinical environment designed for high-quality ECG collection
Early QT and TQT studies require controlled timing, reliable equipment, trained staff and rapid issue resolution during data collection. DVCR helps sponsors execute cardiac assessment studies with a dedicated telemetry room, Hillrom Surveyor™ monitoring, Clario-aligned workflows and safety-focused Phase I conduct.
Early QT/TQT experience
Team with decades of experience supports both Early Precision QT assessments and standalone Thorough QT/QTc studies incorporated into early phase trials.
Clario site champion support
Two DVCR clinical research professionals are certified as Clario Site Champions, helping align study conduct with cardiac safety data requirements.
Dedicated telemetry infrastructure
A dedicated cardiac telemetry room with 48 Hillrom Surveyor™ monitoring channels supports centralized cardiac monitoring and efficient study execution.
Data transmission and visibility
Direct transmission to Clario’s cloud-based portal, on-site cardiac data archiving and remote tracing-quality monitoring support sponsor visibility and data flow.
Reduced collection interruptions
On-site equipment, dedicated Wi-Fi, 12-lead S4 wireless transmitters and remote tracing review help reduce risks such as storage limits, battery failures and poor lead connections.
Safety-focused conduct
A dedicated ACLS-certified safety team and controlled clinic procedures around extraction time points support participant safety and ECG data quality.
Earlier cardiac safety insight can support smarter development decisions
When appropriate, Early QT assessments incorporated into Phase I studies can help sponsors evaluate QT effects earlier in development, inform pipeline decisions and potentially reduce the need for a standalone TQT study later.